SCHEMBL2907882

SCHEMBL2907882

Cc1cc2cccc(Nc3ccc4c(NCc5cccnc5)cccc4n3)c2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 9/20 0.42
ALDH1A1 P00352 7/20 0.40
KDM4E B2RXH2 5/20 0.40
CYP1A2 P05177 6/20 0.40
CYP3A4 P08684 6/20 0.40
CYP2D6 P10635 6/20 0.40
CYP2C19 P33261 6/20 0.40
MEN1 O00255 6/20 0.40
KMT2A Q03164 6/20 0.40
TSHR P16473 5/20 0.40
HSD17B10 Q99714 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
GLA P06280 1/20 0.40
ALOX15 P16050 1/20 0.40
HIF1A Q16665 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
LMNA P02545 3/20 0.39
PDE5A O76074 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901473 0.84 NTRK1 (0.42) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL2907955 0.82 ADRA1A (0.48) TSHRRAB9A
SCHEMBL2906940 0.80 IGF1R (0.34) MAPTALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL2903146 0.79 POLB (0.46) POLBL3MBTL1MAPTALDH1A1KDM4E
SCHEMBL2907384 0.79 QPCT (0.34) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL2901732 0.77 EGFR (0.41) SMN1; SMN2MAPK1NPC1RAB9A
SCHEMBL2908752 0.76 SLC2A1 (0.39) POLBMAPTALDH1A1KDM4EMEN1
SCHEMBL2908896 0.76 LMNA (0.41) POLBL3MBTL1MAPTALDH1A1KDM4E
SCHEMBL2906630 0.74 ACP1 (0.40) MAPTALDH1A1KDM4ECYP1A2CYP3A4
SCHEMBL2906811 0.72 CYP1A2 (0.52) POLBMAPTALDH1A1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825253-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US claimed
EP-2076495-B1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES HOFFMANN LA ROCHE (CH) 2010-08-18 EP claimed
EP-2076495-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F.HOFFMANN-LA ROCHE AG (CH) 2009-07-08 EP claimed
WO-2008037626-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-03 WO claimed
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-04-03 US claimed
US-7825253-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US disclosed
EP-2076495-B1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES HOFFMANN LA ROCHE (CH) 2010-08-18 EP disclosed
EP-2076495-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F.HOFFMANN-LA ROCHE AG (CH) 2009-07-08 EP disclosed
WO-2008037626-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-03 WO disclosed
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES AR, ADRA2C, RCC2 POLB 3619/4885L3MBTL1 3963/4885MAPT 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.